Alamo Biologics LLC filed for Chapter 11 last week after two California companies took steps to collect on a nearly $3.5 million agreed judgment. The San Antonio company said it doesn’t have the money to pay.
Patrick Danner/San Antonio Express-News
Alamo Biologics headquarters, at 5844 Rocky Point Drive on the Northwest Side. The company has filed for bankruptcy protection.
Patrick Danner/San Antonio Express-News
In the 30 years since it was founded, Alamo Biologics LLC became part of San Antonio’s robust regenerative-medicine industry, manufacturing products derived from placental tissue for use in wound care and surgery.
This month, it sought refuge in bankruptcy.
Article continues below this ad
The company filed for Chapter 11 reorganization after a confidential settlement tied to a trade-secret lawsuit devolved into a multimillion-dollar collection fight.
The bankruptcy caps a legal saga that began more than two years ago, when Alamo Biologics was accused of using proprietary manufacturing processes allegedly disclosed by a former executive of a company that owned them.
California-based Human Regenerative Technologies LLC and Skye Orthobiologics LLC sought to collect a judgment of nearly $3.5 million, including asking U.S. District Judge Jason Pulliam in San Antonio to appoint a receiver to take control of some Alamo Biologics assets.
San Antonio Express News Logo
Make us a Preferred Source on Google to see more of us when you search.
Add Preferred Source
PROPERTY WOES: San Antonio doctor at risk of losing chunk of sprawling real estate portfolio
Article continues below this ad
Pulliam granted a preliminary injunction restricting Alamo Biologics from making and selling products at the center o’f the trade-secret dispute before the parties reached a confidential settlement that resulted in the agreed judgment.
It agreed to make interest payments, a $50,000 principal payment and a final $3.4 million balloon payment due Dec. 31. The company made the earlier payments but failed to make the balloon payment, later telling the court it lacked the money to do so.
As Human Regenerative and Skye intensified collection efforts, Alamo Biologics warned that a court order appointing a receiver and directing the turnover of accounts receivable would force it to “terminate its employees” and “close its doors.”
Last week, it told the court that Alamo Biologics and related businesses carried more than $9 million in debt and that accounts receivable were already pledged to secured lenders.
Article continues below this ad
After Alamo Biologic’s bankruptcy filing last Wednesday, Pulliam denied the companies’ request for a receiver, citing the automatic stay on litigation triggered by the Chapter 11 filing.
In its bare-bones petition, Alamo Biologics listed both assets and liabilities in the range of $1 million to $10 million. South Texas Blood & Tissue Center is the largest unsecured creditor based in San Antonio — with a claim of roughly $464,000.
Morris “Trey” White III, a San Antonio lawyer representing Alamo Biologics in the bankruptcy, declined to comment.
Irving attorney James Craig Orr Jr., who represents Human Regenerative and Skye, said he believes the bankruptcy was in response to their collection efforts.
Article continues below this ad
“This is clear because we were set to depose a corporate representative of Alamo on June 11th, and the bankruptcy filing was obviously to avoid that deposition,” he said in an email. He added the $3.4 million remains unpaid.
Tissue bank
Alamo Biologics was founded in 1996 by CEO A. Lee Andrews, who has had a long career in the biologics industry. The company manufactures and distributes human tissue products derived from donated tissue.
Andrews, Precision Allograft Solutions LLC — a subsidiary that processes and sterilizes tissue products — and parent company Dorotea Holding Co. also were named as defendants in the lawsuit but did not seek bankruptcy protection.
Article continues below this ad
The dispute traces its roots to a California lawsuit filed in 2020. Human Regenerative, a California manufacturer of placental tissue products, and affiliated distributor Skye Orthobiologics accused former executive Bryan Banman of using confidential information and trade secrets to launch competing company CTM Biomedical of Toronto and divert customers and business opportunities.
In 2023, a jury found that Banman improperly disclosed confidential manufacturing processes and breached contracts and fiduciary duties while building a competing business. It initially awarded more than $62 million against Banman, including $25.6 million in punitive damages.
However, a federal judge ordered a new trial on the punitive-damages award and the parties reached a settlement in March before that retrial occurred. The parties notified the court they had settled but the settlement terms do not appear in public court records.
READ MORE: San Antonio doctor alleges she was defrauded in health care investment deal
Article continues below this ad
Meanwhile, in early 2024, about three and a half months after the judgment, Human Regenerative and Skye turned around and sued Alamo Biologics in federal court in San Antonio. They alleged Alamo Biologics manufactured for CTM Biomedical competing products using processing methods Banman had improperly disclosed.
According to the complaint, Human Regenerative and Skye sent Alamo Biologics a cease-and-desist letter in December 2023 alleging it was manufacturing CTM Biomedical products using Human Regenerative’s trade secrets. Alamo Biologics’ counsel responded that the company would continue manufacturing the products despite the California judgment against Banman.
In its answer, Alamo Biologics denied misappropriating trade secrets and disputed Human Regenerative’s claim that it possessed protectible trade secrets.
The company argued that any formulas or manufacturing methods at issue were independently developed, lawfully obtained or publicly available. It also contended that the California verdict against Banman could not be used to establish liability against it because it was not a defendant in that case.
Article continues below this ad
‘Close call’
In May 2024, Pulliam granted a preliminary injunction sought by Human Regenerative and Skye, describing his decision as a “close call.” The judge found the companies had shown a substantial likelihood of success on their trade-secret claims and faced irreparable harm if the alleged misuse continued.
The order barred Alamo Biologics from manufacturing or delivering products involved in the dispute while the litigation proceeded.
During a hearing on the injunction request, Alamo Biologics told Pulliam that the proposed injunction could shut down 50% to 60% of its business. In a court filing about that same time, Pamela Sloan, Alamo’s chief financial officer, said the company employed 55 people in San Antonio and warned that the injunction could force layoffs affecting more than a quarter of its workforce. It had 46 employees as of earlier this month, a court filing shows.
Article continues below this ad
Alamo Biologics appealed the injunction, arguing that Human Regenerative was attempting to relitigate trade-secret claims that had already failed in the California case.
The San Antonio company warned the 5th U.S. Circuit Court of Appeals in New Orleans that the injunction threatened a significant portion of the company’s business and could cause lasting financial harm.
SA INC.: Get the week’s top local business stories in your inbox
“Alamo recently expanded its footprint and is opening an additional tissue processing facility at the cost of millions of dollars,” it said in its June 2024 appeal. “Should the injunction continue, without the revenue from CTM Biomedical prevented by the injunction, Alamo will likely be unable to maintain a level of business sufficient to keep this new facility operational, which will likely result in layoffs.”
Article continues below this ad
State records show Alamo Biologics completed a $1.1 million expansion project at 12727 Cimarron Path, close to its headquarters, in 2023 that added cleanroom suites for tissue processing.
Despite Alamo Biologics’ plea, the court declined to halt the order while the appeal was pending.
The appeal ended when both sides agreed to dismiss it in November 2024, a step that came before the settlement that ultimately resolved the case.
Although the June 2025 settlement was confidential, later court filings disclosed the key payment terms, which included the final balloon payment of roughly $3.4 million that was due Dec. 31.
Article continues below this ad
Alamo Biologics made the interest payments and the $50,000 principal payment but failed to make the final balloon payment, later telling the court it didn’t have the money to satisfy the obligation.
Collection efforts
The parties then unsuccessfully attempted to negotiate a new payment arrangement. Human Regenerative and Skye later began collection efforts.
In February, they obtained an abstract of judgment allowing them to record the judgment and pursue collection in other jurisdictions.
Article continues below this ad
They also sought appointment of a receiver to take control of some assets and accounts receivable while pursuing court orders aimed at reaching Andrews’ business interests.
Court records show those efforts included charging orders directing distributions from several Andrews-affiliated businesses to the California companies.
In seeking a receiver, Human Regenerative and Skye argued that court intervention was necessary to preserve and collect assets that could be used to satisfy the judgment.
Alamo Biologics pushed back, warning in a May filing that the appointment of a receiver could force it to terminate employees and close its doors.
Article continues below this ad
The request was never decided on the merits because Alamo Biologics filed for bankruptcy protection June 3, before the court ruled. Pulliam denied the motion without prejudice the next day.
The Chapter 11 filing allows Alamo Biologics to reorganize its debts while continuing to operate.
Its two largest unsecured creditors are Baltimore-based MTF Biologics with a claim of more than $1.4 million and Florida-based Regenerative Biologics Inc., with a nearly $547,000 claim.
Article continues below this ad
The petition contains only limited financial details, with schedules and other required disclosures yet to be filed.